Using DNA nanotechnology to study and regulate immune cells
DNA nanodevices for molecular interrogation and regulation of lymphocytes in adaptive immune system
['FUNDING_OTHER'] · EMORY UNIVERSITY · NIH-11061772
This study is exploring new tools to help us see how immune cells called lymphocytes react to their surroundings, which could lead to better cancer treatments and therapies for autoimmune diseases.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EMORY UNIVERSITY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-11061772 on ClinicalTrials.gov |
What this research studies
This research focuses on developing advanced DNA nanodevices to better understand and manipulate the behavior of lymphocytes, which are crucial components of the adaptive immune system. By creating molecular probes that can visualize and quantify the forces at play within and between cells, the research aims to uncover how these cells respond to mechanical signals. Patients may benefit from improved cancer therapies and treatments for autoimmune conditions as the findings could lead to more effective ways to regulate immune responses.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with cancers or autoimmune disorders who may benefit from enhanced immune regulation.
Not a fit: Patients with stable immune conditions or those not currently undergoing treatment for cancer or autoimmune diseases may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that enhance the effectiveness of cancer treatments and improve management of autoimmune diseases.
How similar studies have performed: Previous research using DNA nanotechnology has shown promise in enhancing biosensing and therapeutic delivery, indicating potential success for this novel approach.
Where this research is happening
ATLANTA, UNITED STATES
- EMORY UNIVERSITY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KE, YONGGANG — EMORY UNIVERSITY
- Study coordinator: KE, YONGGANG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy